Articles |
|
|
|
|
Zirconium oxide ceramic foam: a promising supporting biomaterial for massive production of glial cell line-derived neurotrophic factor |
Zhong-wei Liu, Wen-qiang Li, Jun-kui Wang, Xian-cang Ma, Chen Liang, Peng Liu, Zheng Chu, Yong-hui Dang |
Department of Cardiology, the Third Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710068, China; School of Astronautics, Northwestern Polytechnic University, Xi'an 710072, China; Department of Psychiatry, the First Affiliated Hospital of Xi\'an Jiaotong University, Xi'an 710061, China; Department of Neurosurgery, the First Affiliated Hospital of Xi\'an Jiaotong University, Xi'an 710061, China; College of Medicine & Forensics, Xi\'an Jiaotong University Health Science Center, Xi'an 710061, China; Key Laboratory of the Health Ministry for Forensic Medicine, Health Science Center, Xi\'an Jiaotong University, Xi'an 710061, China; MOE Key Laboratory of Environment and Genes Related to Diseases, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China |
|
|
Abstract This study investigated the potential application of a zirconium oxide (ZrO2) ceramic foam culturing system to the production of glial cell line-derived neurotrophic factor (GDNF). Three sets of ZrO2 ceramic foams with different pore densities of 10, 20, and 30 pores per linear inch (PPI) were prepared to support a 3D culturing system. After primary astrocytes were cultured in these systems, production yields of GDNF were evaluated. The biomaterial biocompatibility, cell proliferation and activation of cellular signaling pathways in GDNF synthesis and secretion in the culturing systems were also assessed and compared with a conventional culturing system. In this study, we found that the ZrO2 ceramic foam culturing system was biocompatible, using which the GDNF yields were elevated and sustained by stimulated cell proliferation and activation of signaling pathways in astrocytes cultured in the system. In conclusion, the ZrO2 ceramic foam is promising for the development of a GDNF mass production device for Parkinson’s disease treatment.
|
Received: 12 June 2014
Published: 03 December 2014
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|